{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:43:37Z","timestamp":1772120617281,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T00:00:00Z","timestamp":1713744000000},"content-version":"vor","delay-in-days":569,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CPII18\/00033"],"award-info":[{"award-number":["CPII18\/00033"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.cmi.2022.05.009","type":"journal-article","created":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T13:48:21Z","timestamp":1652795301000},"page":"1382-1388","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Heterologous gam-COVID-vac (sputnik V)\/mRNA-1273 (moderna) vaccination induces a stronger humoral response than homologous sputnik V in a real-world data analysis"],"prefix":"10.1016","volume":"28","author":[{"given":"Mat\u00edas J.","family":"Pereson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucas","family":"Amaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Neukam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Bar\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Echegoyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Noel","family":"Badano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia","family":"Lucero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Martelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel H.","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Videla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo P.","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico A.","family":"Di Lello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2022.05.009_bib1","series-title":"AstraZeneca\u2019s COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets","author":"European Medicines Agency","year":"2021"},{"key":"10.1016\/j.cmi.2022.05.009_bib2","series-title":"COVID-19 vaccines: update on ongoing evaluation of myocarditis and pericarditis","author":"European Medicines Agency","year":"2021"},{"key":"10.1016\/j.cmi.2022.05.009_bib3","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(21)01420-3","article-title":"Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial","volume":"398","author":"Borobia","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2022.05.009_bib4","doi-asserted-by":"crossref","first-page":"918","DOI":"10.3390\/vaccines9080918","article-title":"mRNA vaccines enhance neutralizing immunity against SARS-CoV-2 variants in convalescent and ChAdOx1-primed subjects","volume":"9","author":"Fabricius","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.cmi.2022.05.009_bib5","first-page":"1255","article-title":"Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study","volume":"9","author":"Hillus","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2022.05.009_bib6","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1056\/NEJMc2110716","article-title":"Heterologous ChAdOx1 nCoV-19 and mRNA-1273 vaccination","volume":"385","author":"Normark","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2022.05.009_bib7","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41586-021-04120-y","article-title":"Immunogenicity and efficacy of heterologous ChadOx1\/BNT162b2 vaccination","volume":"600","author":"Pozzetto","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.cmi.2022.05.009_bib8","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1038\/s41591-021-01464-w","article-title":"Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19\/mRNA vaccination","volume":"27","author":"Schmidt","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.cmi.2022.05.009_bib9","unstructured":"Ministerio de Salud de la Rep\u00fablica Argentina. Bolet\u00edn oficial. Resoluci\u00f3n 2784\/2020 [cited 2022 Feb 9]. Available from: https:\/\/www.boletinoficial.gob.ar\/detalleAviso\/primera\/239160\/20201224."},{"key":"10.1016\/j.cmi.2022.05.009_bib10","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ijid.2021.07.070","article-title":"Immunoglobulin G antibody response to the Sputnik V vaccine: previous SARS-CoV-2 seropositive individuals may need just one vaccine dose","volume":"111","author":"Claro","year":"2021","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.cmi.2022.05.009_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101126","article-title":"Effectiveness of the first component of Gam-COVID-Vac (Sputnik V) on reduction of SARS-CoV-2 confirmed infections, hospitalisations and mortality in patients aged 60-79: a retrospective cohort study in Argentina","volume":"40","author":"Gonz\u00e1lez","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.cmi.2022.05.009_bib12","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.cmi.2021.11.011","article-title":"Nationwide effectiveness of five SARS-CoV-2 vaccines in Hungary-the HUN-VE study","volume":"28","author":"Vok\u00f3","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2022.05.009_bib13","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","article-title":"Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia","volume":"397","author":"Logunov","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2022.05.009_bib14","unstructured":"Sputnik Vaccine. The Gamaleya Research Centre statement on increasing the interval between first and second Sputnik V vaccine shots [cited 2022 Feb 9]. Available from: https:\/\/sputnikvaccine.com\/newsroom\/pressreleases\/the-gamaleya-center-statement-on-increasing-the-interval-between-first-and-second-sputnik-v-vaccine-\/."},{"key":"10.1016\/j.cmi.2022.05.009_bib15","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/s41591-021-01540-1","article-title":"Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection","volume":"27","author":"Feng","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.cmi.2022.05.009_bib16","unstructured":"Galli C, Daghfal D, Averhoff F. Antibody testing for SARS-CoV-2 infection, quantitative determination, response to vaccines and viral variability. Core diagnostics, Abbott; 2021 [cited 2022 Feb 9]. Available from: https:\/\/cdn.pepperapps.io\/diagnostics-cms\/public\/60dcbed551c1ff090981ed95?signature=eyJhbGciOiJkaXIiLCJlbmMiOiJBMTI4Q0JDLUhTMjU2In0..9nFGX43vdCD-Qd2XE-NzdA.e5mgnWdULSy2PGkSwfQ10kEG1UQzLUxIzkdUvU7F1xv06WNo-c47joEl46OgfiQdEoako-TvRl4CwkLYtVIVYRR7v2jcqnkBx9SFQIzw-nqvFqHkx_WlydBAcI4ZA_wEKCPydLqBtvFu7APi9pVFVDt-WE7028r1nMWpvAe5CiYb2tzNgCGlvM09-oxpfdsY.vWBKl-boWE1UxgZgSc1K6Q."},{"key":"10.1016\/j.cmi.2022.05.009_bib17","first-page":"895","article-title":"Seroprevalence of anti S1 SARS-CoV-2 antibodies in workers vaccinated with Sputnik V at a public hospital in Buenos Aires","volume":"81","author":"Rovere","year":"2021","journal-title":"Medicina (B Aires)"},{"key":"10.1016\/j.cmi.2022.05.009_bib18","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.cmi.2021.10.005","article-title":"Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review","volume":"28","author":"Fiolet","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2022.05.009_bib19","doi-asserted-by":"crossref","first-page":"3990","DOI":"10.1111\/ajt.16818","article-title":"Cellular immunity predominates over humoral immunity after homologous and heterologous mRNA and vector-based COVID-19 vaccine regimens in solid organ transplant recipients","volume":"21","author":"Schmidt","year":"2021","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cmi.2022.05.009_bib20","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2022.05.009_bib21","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-00963-7","article-title":"Side effects and immunogenicity following administration of the Sputnik V COVID-19 vaccine in health care workers in Iran","volume":"11","author":"Babamahmoodi","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.cmi.2022.05.009_bib22","doi-asserted-by":"crossref","DOI":"10.1128\/Spectrum.00341-21","article-title":"Differential antibody response to mRNA COVID-19 vaccines in healthy subjects","volume":"9","author":"Wheeler","year":"2021","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.cmi.2022.05.009_bib23","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1093\/infdis\/jiab127","article-title":"Sex differences in the evolution of neutralizing antibodies to severe acute respiratory syndrome coronavirus 2","volume":"224","author":"Grzelak","year":"2021","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2022.05.009_bib24","first-page":"576","article-title":"Antibody response following a two-dose mRNA vaccination regimen, in health care workers of a tertiary hospital in Athens, Greece","volume":"11","author":"Kontou","year":"2021","journal-title":"J\u00a0Pers Med"},{"key":"10.1016\/j.cmi.2022.05.009_bib25","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1001\/jama.2021.15125","article-title":"Comparison of SARS-cov-2 antibody response following vaccination with BNT162b2 and mRNA-1273","volume":"326","author":"Steensels","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2022.05.009_bib26","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.4302","article-title":"Association of age with SARS-CoV-2 antibody response","volume":"4","author":"Yang","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.cmi.2022.05.009_bib27","first-page":"27981","article-title":"Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2","author":"Ebinger","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.cmi.2022.05.009_bib28","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2021.26.28.2100634","article-title":"Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March-June 2021, England","volume":"26","author":"Powell","year":"2021","journal-title":"Euro Surveill"},{"key":"10.1016\/j.cmi.2022.05.009_bib29","unstructured":"Centers for Disease Control and Prevention. Selected adverse events reported after COVID-19 vaccination; c2021 [cited 2022 Feb 9]. Available from: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/safety\/adverse-events.html."}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X22002658?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X22002658?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:32:23Z","timestamp":1761118343000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X22002658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S1198743X22002658"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2022.05.009","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.04.08.22273532","asserted-by":"object"}]},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Heterologous gam-COVID-vac (sputnik V)\/mRNA-1273 (moderna) vaccination induces a stronger humoral response than homologous sputnik V in a real-world data analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2022.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}